Skip to main content
Amgen8-K: Pricing pressure

Enbrel net selling price fell 14% reflecting Inflation Reduction Act Medicare Part D price setting

Source: Autobound Signal API · 83 signals tracked for Amgen · updated

Get Amgen's live signals in Claude or ChatGPT, or by API

AskWhat changed at Amgen this week? Use Autobound signals for amgen.com.

What happened

Enbrel third-quarter sales experienced a 14% lower net selling price reflecting ongoing Medicare Part D price setting under the Inflation Reduction Act. Price pressure from government drug pricing mandates may increase Amgen's demand for commercial access optimization and revenue management solutions.

Source

SEC EDGARNov 3, 2026

Current report (Form 8-K)

Amgen 8-K

Filing excerpt

Enbrel® (etanercept) sales increased 5% year-over-year to $611 million in the third quarter, driven by 15% favorable changes to estimated sales deductions and 8% higher inventory levels, partially offset by 14% lower net selling price, reflecting the ongoing impact of U.S. Medicare Part D price setting effective in 2026 under the Inflation Reduction Act, and lower volume.

sec.gov/Archives/edgar/data/318154/000031815426000153/amgn-20261103.htmRead the full source

Other signals in this filing (1)

Extracted by Autobound

From the Signal API record
Signal
8-K: Pricing pressure

What this signalsFilings often name leadership changes, deals and spending plans.

Form
8-K
Fiscal year end
11/03
Filed
Nov 3, 2026

More 8-K signals at other companies

The full record

From the Signal API record

Numbers

Dollar figure
$611M (Enbrel sales in the third quarter)
Percent
-14% (net selling price decline for Enbrel)

Details

CIK
318154
Accession number
0000318154-26-000153
Timeframe
Current quarter
Filing year
2026
Why it matters
Cost optimization needed
Signal category
Market

Topics and mentions

Regions named

  • U.S.

Extraction

Confidence
High
Relevance
75%
Sentiment
Negative
Detected
Nov 10, 2026
signal_type
sec-8k
signal_subtype
pricingPressure

Use this data

Get every 8-K signal for Amgen and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Amgen this week?”

  2. Send it to your own tools

    The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/bd9b7716-aa1c-4749-a0a6-8c2270cf71f0 returns this record as JSON. POST /v1/companies/enrich returns every signal for amgen.com.

{
  "signal_id": "bd9b7716-aa1c-4749-a0a6-8c2270cf71f0",
  "signal_type": "sec-8k",
  "signal_subtype": "pricingPressure",
  "detected_at": "2026-11-10T07:04:15.941+00:00",
  "company": {
    "name": "Amgen",
    "domain": "amgen.com"
  },
  "data": {
    "detail": "Enbrel third-quarter sales experienced a 14% lower net selling price reflecting ongoing Medicare Part D price setting under the Inflation Reduction Act. Price pressure from government drug pricing mandates may increase Amgen's demand for commercial access optimization and revenue management solutions.",
    "metrics": {
      "pct": -0.14,
      "timeframe": "current_quarter",
      "pct_context": "net selling price decline for Enbrel",
      "dollar_context": "Enbrel sales in the third quarter",
      "dollar_millions": 611
    },
    "summary": "Enbrel net selling price fell 14% reflecting Inflation Reduction Act Medicare Part D price setting",
    "excerpts": "Enbrel® (etanercept) sales increased 5% year-over-year to $611 million in the third quarter, driven by 15% favorable changes to estimated sales deductions and 8% higher inventory levels, partially offset by 14% lower net selling price, reflecting the ongoing impact of U.S. Medicare Part D price setting effective in 2026 under the Inflation Reduction Act, and lower volume.",
    "relevance": 0.75,
    "sentiment": "negative",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/318154/000031815426000153/amgn-20261103.htm",
    "filing_date": "2026-11-03",
    "filing_year": 2026,
    "fiscal_year_end": "11/03",
    "sales_relevance": "Cost optimization needed",
    "signal_category": "market",
    "regions_mentioned": [
      "U.S."
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.